These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 24958351

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.
    Yeh ES, Abt MA, Hill EG.
    Breast Cancer Res Treat; 2015 Jan; 149(1):91-8. PubMed ID: 25515931
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
    Dragowska WH, Weppler SA, Qadir MA, Wong LY, Franssen Y, Baker JH, Kapanen AI, Kierkels GJ, Masin D, Minchinton AI, Gelmon KA, Bally MB.
    BMC Cancer; 2011 Oct 01; 11():420. PubMed ID: 21961653
    [Abstract] [Full Text] [Related]

  • 26. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
    Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Torres-Garcia VZ, Sauri-Nadal T, Barco SD, Lopez-Bonet E, Brunet J, Martin-Castillo B, Menendez JA.
    Biochem Biophys Res Commun; 2011 Apr 08; 407(2):412-9. PubMed ID: 21402055
    [Abstract] [Full Text] [Related]

  • 27. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
    Borrero-García LD, Del Mar Maldonado M, Medina-Velázquez J, Troche-Torres AL, Velazquez L, Grafals-Ruiz N, Dharmawardhane S.
    BMC Cancer; 2021 Jun 01; 21(1):652. PubMed ID: 34074257
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
    O'Shea J, Cremona M, Morgan C, Milewska M, Holmes F, Espina V, Liotta L, O'Shaughnessy J, Toomey S, Madden SF, Carr A, Elster N, Hennessy BT, Eustace AJ.
    Oncotarget; 2017 Oct 17; 8(49):85120-85135. PubMed ID: 29156708
    [Abstract] [Full Text] [Related]

  • 31. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
    Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL.
    Clin Cancer Res; 2013 Feb 01; 19(3):610-9. PubMed ID: 23224399
    [Abstract] [Full Text] [Related]

  • 32. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
    Collins DM, Gately K, Hughes C, Edwards C, Davies A, Madden SF, O'Byrne KJ, O'Donovan N, Crown J.
    Cell Immunol; 2017 Sep 01; 319():35-42. PubMed ID: 28735814
    [Abstract] [Full Text] [Related]

  • 33. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
    Vazquez-Martin A, Oliveras-Ferraros C, Colomer R, Brunet J, Menendez JA.
    Ann Oncol; 2008 Jun 01; 19(6):1097-109. PubMed ID: 18283037
    [Abstract] [Full Text] [Related]

  • 34. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.
    Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, Chamness GC, Reis-Filho JS, Weigelt B, Heiser LM, Hilsenbeck SG, Huang S, Rimawi MF, Gray JW, Osborne CK, Schiff R.
    Mol Cancer Res; 2019 Nov 01; 17(11):2318-2330. PubMed ID: 31420371
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
    Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM.
    Cancer Res; 2009 Sep 01; 69(17):6871-8. PubMed ID: 19671800
    [Abstract] [Full Text] [Related]

  • 37. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
    Collins DM, Madden SF, Gaynor N, AlSultan D, Le Gal M, Eustace AJ, Gately KA, Hughes C, Davies AM, Mahgoub T, Ballot J, Toomey S, O'Connor DP, Gallagher WM, Holmes FA, Espina V, Liotta L, Hennessy BT, O'Byrne KJ, Hasmann M, Bossenmaier B, O'Donovan N, Crown J.
    Clin Cancer Res; 2021 Feb 01; 27(3):807-818. PubMed ID: 33122343
    [Abstract] [Full Text] [Related]

  • 38. Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells.
    Ma C, Zuo W, Wang X, Wei L, Guo Q, Song X.
    Oncol Rep; 2013 Feb 01; 29(2):812-8. PubMed ID: 23229346
    [Abstract] [Full Text] [Related]

  • 39. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
    Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, Baselga J.
    J Natl Cancer Inst; 2007 Apr 18; 99(8):628-38. PubMed ID: 17440164
    [Abstract] [Full Text] [Related]

  • 40. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
    O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ.
    Mol Cancer Ther; 2010 Jun 18; 9(6):1489-502. PubMed ID: 20501798
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.